Enzymatic vitreous disruption

Eye

Volumn 22, Issue 10, 2008, Pages 1273-1277

  Gandorfer, A ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DISPASE; HYALURONIDASE; N ACETYLGALACTOSAMINE 4 SULFATASE; PLASMIN; RECOMBINANT ENZYME; RECOMBINANT MICROPLASMIN; RECOMBINANT PLASMINOGEN[LYSINE]; RECOMBINANT UROKINASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG SAFETY; ENZYMATIC VITREOUS DISRUPTION; EPIRETINAL MEMBRANE; HUMAN; LIQUEFACTION; NONHUMAN; RETINA MACULA HOLE; RETINA MACULOPATHY; SURGICAL TECHNIQUE; VITRECTOMY; VITREORETINOPATHY; VITREOUS BODY DETACHMENT; VITREOUS HEMORRHAGE;

EID: 54249136755     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2008.29     Document Type: Conference Paper

References (41)

1. Schwartz SD, Alexander R, Hiscott P, Gregor ZJ. Recognition of vitreoschisis in proliferative diabetic retinopathy. A useful landmark in vitrectomy for diabetic traction retinal detachment. Ophthalmology 1996; 103: 323-328.
2. Nasrallah FP, Jalkh AE, Van Coppenolle F, Kado M, Trempe CL, McMeel JW et al. The role of the vitreous in diabetic macular edema. Ophthalmology 1988; 95: 1335-1339.
3. Bonnet M. The development of severe proliferative vitreoretinopathy after retinal detachment surgery. Grade B: A determining risk factor. Graefes Arch Clin Exp Ophthalmol 1988; 226: 201-205.
4. Capeans, C, Lorenzo J, Santos L, Suarez A, Copena MJ, Blanco MJ et al Comparative study of incomplete posterior vitreous detachment as a risk factor for proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol 1998; 236: 481-485.
5. Gandorfer A, Rohleder M, Kampik A. Epiretinal pathology of vitreomacular traction syndrome. Br J Ophthalmol 2002; 86: 902-909.
6. Trese M. Enzymatic-assisted vitrectomy. Eye 2002; 16: 365-368.
7. Gandorfer A, Ulbig M, Kampik A. Plasmin-assisted vitrectomy eliminates cortical vitreous remnants. Eye 2002; 16: 95-97.
8. Gandorfer A, Rohleder K Grosselfinger S, Haritoglou C, Ulbig M, Kampik A. Epiretinal pathology of diffuse diabetic macular edema associated with vitreomacular traction. Am J Ophthalmol 2005; 139: 638-652.
9. Stefansson E, Landers III MB, Wolbarsht ML. Vitrectomy, lensectomy, and ocular oxygenation. Retina 1982; 2: 159-166.
10. Verma L, Prakash G, Tewari HK. Diabetic retinopathy: Time for action. No complacency please!. Bull World Health Organ 2002, 80: 419.
11. Sebag J. Pharmacologic vitreolysis. Retina 1998, 18: 1-3.
12. Hageman GS, Russell SR. Chondroitinase-mediated disinsertion of the primate vitreous body. Invest Ophthalmol Vis Sci 1994; 35: 1260.
13. Bishop P. The biochemical structure of mammalian vitreous. Eye 1996; 10: 664-670.
14. Sebag J. The vitreous. Structure, function, pathobiology. Springer Verlag: New York, 1989.
15. Asakura A. Histochemistry of hyaluronic acid of the bovine vitreous body by electromicroscopy. Nippon Ganka Gakkai Zasshi 1985; 89: 179-191.
16. Kuppermann BD, Thomas EL, de Smet MD, Grillone LR. Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemmorrhage. Am J Ophthalmol 2005; 140: 573-584.
17. Kuppermann BD, Thomas EL, de Smet MD, Grillone LR. Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol 2005; 140: 585-597.
18. Hikichi T, Kado M, Yoshida A. Intravitreal injection of hyaluronidase cannot induce posterior vitreous detachment in the rabbit. Retina 2000; 20: 195-198.
19. Stenn KS, Link R, Moelmann G. Dispase, a neutral protease from Bacillus polymyxa, is a powerful fibronectinase and type IV collagenase. J Invest Dermatol 1989; 93: 287-290.
20. Tezel TH, Del Priore LV, Kaplan HJ. Posterior vitreous detachment with dispase. Retina 1998; 18: 7-15.
21. Oliveira LB, Tatebayashi M, Mahmoud TH, Blackmon SM, Wong F, McCuen II BW, Dispase facilitates posterior vitreous detachment during vitrectomy in young pigs. Retina 2001; 21: 324-331.
22. Jorge R, Oyamaguchi EK, Cardillo JA, Gobbi A, Laicine EM, Haddad A. Intravitreal injection of dispase causes retinal hemorrhages in rabbit and human eyes. Curr Eye Res 2003; 26: 107-112.
23. Frenzel EM, Neely KA, Walsh AW, Cameron JD, Gregerson DS. A new model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1998; 39: 2157-2164.
24. Kohno T, Sorgente N, Ishibashi T, Goodnight R. Ryan SJ. Immunofluorescent studies of fibronectin and laminin in the human eye. Invest Ophthalmol Vis Sci 1987; 28: 506-514.
25. Kohno T, Sorgente N, Goodnight R, Ryan SJ. Alterations in the distribution of fibronectin and laminin in the diabetic human eye. Invest Ophthalmol Vis Sci 1987, 28: 515-521.
26. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 1981; 41: 4629-4636.
27. Verstraeten TC, Chapman C, Hartzer M, Winkler BS, Trese MT, Williams GA. Pharmacologic induction of posterior vitreous detachment in the rabbit. Arch Ophthalmol 1993; 111: 849-854.
28. Hikichi T, Yanagiya N, Kado M, Akiba J, Yoshida A. Posterior vitreous detachment induced by injection of plasmin and sulfur hexafluoride in the rabbit vitreous. Retina 1999; 19: 55-58.
29. Gandorfer A, Putz E, Welge-Lussen U, Gruterich M, Ulbig M, Kampik A. Ultrastructure of the vitreoretinal interface following plasmin assisted vitrectomy. Br J Ophthalmol 2001; 85: 6-10.
30. Gandorfer A, Priglinger S, Schebitz K, Hoops J, Ulbig M, Ruckhofer J et al. Vitreoretinal morphology of plasmin-treated human eyes. Am J Ophthalmol 2002; 133: 156-159.
31. Li X, Shi X, Fan J. Posterior vitreous detachment with plasmin in the isolated human eye. Graefes Arch Clin Exp Ophthalmol 2002; 240 56-62.
32. Hesse L, Nebeling B, Schroeder B, Heller G, Kroll P. Induction of posterior vitreous detachment in rabbits by intravitreal injection of tissue plasminogen activator following cryopexy. Exp Eye Res 2000; 70: 31-39.
33. Hesse L, Chofflet J, Kroll P. Tissue plasminogen activator as a biochemical adjuvant in vitrectomy for proliferative diabetic vitreoretinopathy. Ger J Ophthalmol 1995, 4: 323-327.
34. Le Mer Y, Korobelnik JF, Morel C, Ullern M, Berrod JP. TPA-assisted vitrectomy for proliferative diabetic retinopathy: Results of a double-masked, multicenter trial. Retina 1999, 19: 378-382.
35. Men G, Peyman GA, Genaidy M, Kuo PC, Ghahramani F, Blake DA et al. The role of recombinant lysine-plasminogen and recombinant urokinase and sulfur hexafluoride combination in inducing posterior vitreous detachment. Retina 2004; 24: 199-209.
36. Margherio AF, Margherio RR, Hartzer M, Trese MT, Williams GA, Ferrone PJ. Plasmin enzyme-assisted vitrectomy in traumatic pediatric macular holes. Ophthalmology 1998; 105: 1617-1620.
37. Trese MT, Williams GA, Hartzer MK. A new approach to stage 3 macular holes. Ophthalmology 2000; 107: 1607-1611.
38. William JG, Trese MT, Williams GA, Hartzer MK. Autologous plasmin enzyme in the surgical management of diabetic retinopathy. Ophthalmology 2001; 108: 1902-1905.
39. Gandorfer A, Rohleder M, Sethi C, Eckle D, Welge-Lussen U, Kampik A et al. Posterior vitreous detachment induced by microplasmin. Invest Ophthalmol Vis Sci 2004; 45: 641-647.
40. Sakuma T, Tanaka M, Mizota A, Inoue J, Pakola S. Safety of in vivo pharmacologic vitreolysis with recombinant microplasmin in rabbit eyes. Invest Ophthalmol Vis Sci 2005; 46: 3295-3299.
41. Sebag J, Ansari RF, Suh KI. Pharmacologic vitreolysis with microplasmin increases vitreous diffusion coefficients. Graefes Arch Clin Exp Ophthalmol 2007; 245: 576-580.